Position in MBX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$35,880,000
+$16,477,500 QoQ
Shares Held
650,000
0.0% QoQ
Ownership
1.35%
of shares outstanding
% of Portfolio
0.86%
of 13F equity value
Holder Rank
#22
of 172 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MBX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TCG Crossover Management, LLC holds $3,891,479,135 across 48 Biotechnology names. MBX ranks #28 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
6,007,834 | $800,603,958 | |
| 2 | TNGX |
Tango Therapeutics, Inc.
|
9,081,201 | $283,878,343 | |
| 3 | CGON |
CG Oncology, Inc.
|
3,670,206 | $260,768,136 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,854,436 | $187,866,673 | |
| 5 | IMVT |
Immunovant, Inc.
|
4,457,988 | $171,766,277 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,900,582 | $168,733,669 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,676,624 | $163,437,307 | |
| 8 | MIRM |
Mirum Pharmaceuticals, Inc.
|
1,062,049 | $124,334,076 |
All Filings in MBX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $35,880,000 | 650,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $19,402,500 | 650,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $20,501,000 | 650,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $11,375,000 | 650,000 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $7,416,500 | 650,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,797,000 | 650,000 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $11,979,500 | 650,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $16,887,000 | 650,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||